Patents Assigned to Sfunga Therapeutics, Inc.
  • Derivatives of amphotericin B
    Patent number: 10882883
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: January 5, 2021
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 10597420
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: March 24, 2020
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun
  • Derivatives of amphotericin B
    Patent number: 9957290
    Abstract: Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3?-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2?epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: May 1, 2018
    Assignee: Sfunga Therapeutics, Inc.
    Inventors: Martin D. Burke, Arun P. Thottumkara, Kevin T. Mellem, Zachary K. Sweeney, Elena S. Koltun